Mark C. Schneyer - 01 May 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP, CHIEF FINANCIAL OFFICER
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 01 May 2025
Net transactions value: -$51,071
Form type: 4
Filing time: 02 May 2025, 19:59:08 UTC
Previous filing: 08 Apr 2025
Next filing: 19 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO	/s/ Jennifer J. Rhodes, Attorney-in-Fact	02 May 2025	0001899977

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+6,815	+11%		66,271	01 May 2025	Direct	F1
transaction	ACAD	Common Stock	Sale	$51,071	-3,498	-5.3%	$14.60	62,773	02 May 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-6,815	-33%	$0.000000	13,630	01 May 2025	Common Stock	6,815		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3	The restricted stock units vest in four equal annual installments beginning May 1, 2024.